Dr. Johnson-Pratt has been a director since 2021. Dr. Johnson-Pratt has served as Executive Vice President, Therapeutic Program Lead at Aspen Neurosciences since October 2024, where she previously served as Senior Vice President, Therapeutic Program Lead from January 2024 until October 2024. In September 2019, Dr. Johnson-Pratt founded Ananias Ventures and has served as Biotechnology, Cell and Gene Therapy Strategic Commercial Advisor there since June 2022. From November 2020 until May 2022, she served as Senior Vice President, New Product Commercial Strategy at Ionis Pharmaceuticals. She joined Ionis following its acquisition of Akcea Therapeutics where she served as Senior Vice President, New Product Strategy and was responsible for the commercialization strategy for three late-stage rare disease programs. Prior to that, Dr. Johnson-Pratt spent several years at GlaxoSmithKline (GSK) as Head of Early Pipeline Commercial Strategy and Head of Global Commercial Pharma Center of Excellence leading oncology early commercial strategy. Earlier in her career, Dr. Johnson-Pratt also served in leadership roles at GlaxoWellcome; Stiefel, a GSK company; and Merck & Co. Dr. Johnson-Pratt is the founder of Ananias Ventures, which supports projects focused on issues related to vulnerable women and children. She previously served on the board of directors of TRACON Pharmaceuticals, then a public biopharmaceutical company, from March 2021 until 2024, and currently serves on the board of directors of Young People in Recovery, a national non-profit that supports young people to thrive after recovering from substance abuse. Dr. Johnson-Pratt received her medical degree from, and completed her residency in Internal Medicine at, Howard University. She completed a Fellowship in Clinical Pharmacology and Pharmaceutical Medicine at Howard University. She holds a Diploma of Pharmaceutical Medicine from the Royal College of Physicians.